News - Biosimilars, Janssen

Filter

Current filters:

BiosimilarsJanssen

Popular Filters

1 to 25 of 163 results

Epirus to acquire Zalicus, creating a publicly-traded biosimilars enterprise

16-04-2014

Boston-based privately-held Epirus Biopharmaceuticals, focused on the global development and commercialization…

BiosimilarsBiotechnologyEPIRUS BiopharmaceuticalsMergers & AcquisitionsZalicus

Topamax safety concerns as a treatment for migraines in adolescents, despite recent FDA approval

Topamax safety concerns as a treatment for migraines in adolescents, despite recent FDA approval

11-04-2014

The US Food and Drug Administration’s recent approval of Johnson & Johnson subsidiary Janssen’s Topamax…

JanssenJohnson & JohnsonMarkets & MarketingNeurologicalPharmaceuticalRegulationTopamax

EGA president seeks partnership with Italian government on generics and biosimilars

09-04-2014

The president of the European Generic Medicines Association (EGA), Nick Haggar, attended the Stati Generali…

BiosimilarsEuropeGenericsItalyMarkets & MarketingPolitics

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

07-04-2014

Uptake of biosimilars in Europe has increased as a result of member states’ policies, according to…

BiosimilarsEuropeFilgrastimInterviewsMarkets & MarketingRegulationSandoz

EGA Biosimilars: European monitoring and global business opportunities

EGA Biosimilars: European monitoring and global business opportunities

07-04-2014

The spotlight was on the European uptake of biosimilars at the European Generic medicines Association’s…

BiosimilarsEuropeGlobalInterviewsMarkets & Marketing

EGA Biosimilars: Call for regulatory authorities to improve awareness of biosimilars

EGA Biosimilars: Call for regulatory authorities to improve awareness of biosimilars

04-04-2014

Clear and unbiased information on biosimilars is needed to increase uptake of the medicines across Europe,…

BiosimilarsEurope

Fast growth forecast for South Korean pharma market

Fast growth forecast for South Korean pharma market

02-04-2014

South Korea's pharmaceuticals market was valued at $20 billion in 2012, growing from $14.5 billion in…

Asia-PacificBiosimilarsBiotechnologyMarkets & MarketingPricingResearch

Janssen files new NDA for combination HIV drug containing darunavir

Janssen files new NDA for combination HIV drug containing darunavir

01-04-2014

US health care giant Johnson & Johnson’s Europe-based subsidiary Janssen has submitted a New Drug Application…

Anti-viralsDarunavirJanssenPharmaceuticalPrezistaRegulationUSA

UK’s NICE does not recommend Janssen’s Stelara for psoriatic arthritis

UK’s NICE does not recommend Janssen’s Stelara for psoriatic arthritis

28-03-2014

Final draft guidance from the UK health care costs watchdog the National Institute for Health and Care…

Anti-Arthritics/RheumaticsJanssenJohnson & JohnsonNorthern EuropePharmaceuticalPricingRegulationStelara InjectionUK

Real world data shows that Stelara offers lower rates of psoriasis infection

Real world data shows that Stelara offers lower rates of psoriasis infection

27-03-2014

New interval findings from an international prospective disease-based registry provide a review of important…

DermatologicalsJanssenPharmaceuticalResearchStelara InjectionUSA

Janssen’s guselkumab shows significant efficacy in moderate to severe plaque psoriasis

25-03-2014

New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology…

DermatologicalsguselkumabHumiraJanssenJohnson & JohnsonPharmaceuticalResearch

Positive CHMP opinion for Janssen’s simeprevir for chronic hepatitis C

24-03-2014

US health care giant Johnson & Johnson’s European subsidiary Janssen R&D Ireland has received a positive…

Anti-viralsEuropeJanssenJohnson & JohnsonMedivirOlysioPharmaceuticalRegulationsimeprevir

UK NICE backs Janssen’s Velcade for multiple myeloma

UK NICE backs Janssen’s Velcade for multiple myeloma

21-03-2014

In new draft guidance published today, UK drugs watchdog the National Institute for Health and Care Excellence…

JanssenJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

Janssen stops Ph III schizophrenia trial on good efficacy and relapse results

Janssen stops Ph III schizophrenia trial on good efficacy and relapse results

20-03-2014

Following an Independent Data Monitoring Committee recommendation based on positive efficacy, a Johnson…

Invega SustennaJanssenJohnson & JohnsonNeurologicalpaliperidone palmitatePharmaceuticalResearch

Pan-European survey calls for a shift in policy for biosimilars

Pan-European survey calls for a shift in policy for biosimilars

19-03-2014

This week, the Alliance for Safe Biologic Medicines (ASBM) disclosed the results of a survey of 470 European…

BiosimilarsBiotechnologyEuropeHealthcareRegulation

EGA calls for removal of barriers to competition and free trade for generics

EGA calls for removal of barriers to competition and free trade for generics

19-03-2014

The European Union must remove barriers to competition and free trade by introducing common sense reforms…

BiosimilarsEuropeGenericsMarkets & MarketingPatentsRegulation

Positive new Ph III data from once-daily simeprevir presented at APASL

18-03-2014

Encouraging new Phase III data for the once-daily protease inhibitor simeprevir (trade name Olysio in…

Anti-viralsJanssenJohnson & JohnsonMedivirOlysioPharmaceuticalResearchsimeprevir

India now making moves into pharma innovation

India now making moves into pharma innovation

03-03-2014

In what must be seen as a significant change in focus, India is now seeing a surge of innovative research…

Asia-PacificBiosimilarsIndiaMarkets & MarketingPharmaceuticalResearch

BIO urges Indiana Governor to sign Bill on interchangeable biologic medicines

27-02-2014

US trade group the Biotechnology Industry Organization (BIO) and the Indiana Health Industry Forum (IHIF)…

BiosimilarsGenericsLegalNorth AmericaRegulationUSA

Teva UK launches Lonquex, a new long-acting G-CSF competitor to Amgen drugs

Teva UK launches Lonquex, a new long-acting G-CSF competitor to Amgen drugs

26-02-2014

The local subsidiary of Israeli generics giant Teva Pharmaceutical Industries has launched Lonquex (lipegfilgrastim)…

AmgenBiosimilarsGenericsLonquexMarkets & MarketingNorthern EuropeOncologyTeva Pharmaceutical IndustriesUK

Merck names Simon Sturge as new head of biosimilars unit

Merck names Simon Sturge as new head of biosimilars unit

20-02-2014

Germany’s Merck KGaA has appointed Simon Sturge to head the biosimilars unit, effective March 1, succeeding…

BiosimilarsBiotechnologyBoardroomManagementMerck KGaA

1 to 25 of 163 results

Back to top